key: cord-0966258-t89hys9i authors: Kroumpouzos, George title: Cutaneous manifestations of COVID‐19: An unusual presentation with edematous plaques and pruritic, erythematous papules, and comment on the role of bradykinin storm and its therapeutic implications date: 2021-01-13 journal: Dermatol Ther DOI: 10.1111/dth.14753 sha: bfd4ffe64de4949b92873e076103d5620f0d2ea8 doc_id: 966258 cord_uid: t89hys9i nan Cutaneous manifestations of COVID-19: An unusual presentation with edematous plaques and pruritic, erythematous papules, and comment on the role of bradykinin storm and its therapeutic implications 4 The kallikrein-kinin system (KKS) results in bradykinin production and is linked with the contact system (CS). It has been suggested that the CS plays a pivotal role in the innate immune response against SARS-CoV-2, and that a kinin-dependent local lung angioedema via bradykinin B1 and eventually B2 receptor occurs. 5 The bradykinin theory fits with a surprising number of COVID-19's unique manifestations. 4 Bradykinin-induced vasodilation and enhanced vascular permeability-edema can translate in edematous, urticarial-looking lesions and erythematous eruptions. Increased vascular permeability could also explain "Covid toes". 6 Also, bradykinin causes pain F I G U R E 1 Edematous plaques (black arrow) and pruritic papules (red arrows) are shown on the dorsum of right hand and itching and has an overall pro-inflammatory effect. 7 Bradykinin receptors increase chemotaxis of neutrophils, and neutrophils engage KKS to open up the endothelial barrier in acute inflammation. 8, 9 Furthermore, activation of bradykinin receptors increases the levels of interleukin 6, an inflammatory cytokine that appears to correlate with disease severity. 5 These effects increase the trend towards inflammation that already exists secondary to increased cytokine production in COVID-19. There is possibly interplay between bradykinin-related mechanisms and immune response (cytokine) effects when it comes to tissue inflammation in COVID-19. Activation of coagulation/fibrinolysis system, which is part of CS, can result in pathologic thrombus formation and often occurs simultaneously with activation of KKS (bradykinin production). 5 The above mechanisms could underlie most cutaneous manifestations of COVID-19, especially those involving edema and inflammation. Bradykinin receptor antagonists may have beneficial effects on skin manifestations related to COVID-19, and it would be worth trying them in large-scale studies. Cutaneous manifestations of COVID-19: an evidence-based review skin histopathological manifestations and relationship to COVID-19 infection patients Cutaneous manifestations in COVID-19: a new contribution Bradykinin as a probable aspect in SARS-Cov-2 scenarios: is bradykinin sneaking out of our sight? Understanding the pathophysiology of COVID-19: could the contact system be the key? Front Immunol Vascular skin symptoms in COVID-19: a french observational study Bradykinin-evoked scratching responses in complete Freund's adjuvant-inflamed skin through activation of B1 receptor Activation of kinin B1 receptors induces chemotaxis of human neutrophils Neutrophils engage the kallikreinkinin system to open up the endothelial barrier in acute inflammation The authors declare no potential conflict of interest. The data that support the findings of this study are available from the